Coriolis Pharma

What Coriolis Pharma does

Coriolis Pharma is a privately-held contract research and development organization (CRDO) founded in 2008 in Martinsried, Germany, by Prof. Dr. Gerhard Winter of LMU Munich. The company specializes in formulation research, analytical services, and drug product manufacturing for biopharmaceutical drugs across multiple therapeutic modalities, including monoclonal antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, and vaccines. It serves pharmaceutical and biotech clients ranging from early-stage developers to large multinational pharmaceutical corporations, supporting projects from preclinical development through commercialization.

Coriolis operates a three-pillar service platform: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services under both R&D and GMP conditions, and Manufacturing Services for liquid and lyophilized drug products. Its proprietary COR-Competences® platform codifies 18 years of formulation science into standardized analytical workflows. The company integrates AI, machine learning, and digital twin technologies into its formulation development pipelines to predict drug candidate formulatability at late discovery stage and optimize formulations for clinical studies. Notable technical capabilities include SV-AUC methodology optimized for AAV gene therapy vectors (achieving up to 20-fold sample consumption reduction) and proprietary analytical approaches for particle identification and surfactant characterization.

The company generates revenue through project-based contracts for preclinical through commercial-stage services, with pricing managed via a consultative 'Request a Quote' model. Scale metrics include 845 global clients, 2,900+ completed projects, 980+ biotherapeutics supported, 165 formulations developed, 20 commercial products supported, and 160 peer-reviewed publications. In October 2023, KKR and Frontier Biosolutions executed a strategic growth investment to support global expansion and AI capability development, and in March 2026 Coriolis opened a US headquarters and laboratory in Durham, North Carolina.

Name

Coriolis Pharma

Legal name

Coriolis Pharma Research GmbH

Website

https://coriolis-pharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Coriolis Pharma is a Germany-based contract research and development organization specializing in biologics formulation, analytical services, and drug product manufacturing for pharmaceutical and biotech clients across multiple therapeutic modalities.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Formulation & Drug Product Development Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Biologics formulation development
• Drug product development
• Analytical services
• Contract research organization
• GMP manufacturing services

Headquarters

HQ city

Martinsried

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research & Development Services: Coriolis Pharma operates as a contract research and development organization (CRDO) providing formulation research, analytical services, and manufacturing services to pharmaceutical and biotech clients. Services are billed on a project/contract basis, likely through fixed-price or time-and-materials contracts. Revenue is generated from preclinical through commercial stage projects across multiple therapeutic modalities including antibodies, peptides, gene & cell therapy, viral vectors, nucleic acids, and vaccines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Coriolis Pharma is an independent contract research and development organization (CRDO) providing formulation research, analytical services, and GMP manufacturing services for biopharmaceutical drugs across multiple biological modalities (antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems). The company delivers project-based services spanning preclinical, early-phase, late-phase, and commercial stages, supported by its proprietary COR-Competences analytical platform and in silico / AI / digital twin formulation modeling capabilities.

Product overview

Coriolis Pharma is a contract research and development organization (CRDO) providing integrated drug product development, analytical services, and manufacturing services across multiple biological therapeutic modalities. The company operates a platform-based service model consisting of three core service pillars: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services (R&D and GMP), and Manufacturing Services (liquid and lyophilized drug products). Services span across therapeutic modalities including antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems. Development phases covered range from preclinical through commercial. The company also offers specialized computational capabilities using AI and machine learning for in silico formulation prediction and digital twin development.

Differentiator

Problem solved

Functional benefit

Brands

• COR-Competences®: Standardized analytical approaches built on 18 years of experience in drug product development, academic and applied research projects and continuous learning.

Products and services

• Drug Product Development Services Comprehensive formulation development services for biopharmaceutical drugs including preformulation studies, formulation development, lyophilization process development, comparability studies, stability studies, and biopharmaceutical process development, offered to pharmaceutical and biotech clients across development stages.
• Analytical Services (R&D and GMP) Comprehensive analytical testing under R&D and GMP conditions including method development and validation, aggregate analytics, particle characterization, particle identification, surfactant characterization, higher-order structure analysis, functional assays, chemical change analysis, lyophilizate analytics, container closure integrity testing, basic formulation characterization, stability testing, and release testing for biologics.
• Manufacturing Services (Liquid and Lyophilized) GMP process development and manufacturing services for liquid and lyophilized drug products, including manufacturing troubleshooting and support for biologics and ATMPs from preclinical through commercial stages.
• Accelerator Development Platforms Platform services for monoclonal antibody and antibody-like programs designed to accelerate preclinical and early-phase development, covering formulation screening, developability assessment, preformulation studies, and formulation development to enable rapid clinic entry.
• In Silico Formulation Modeling Computational modeling services using AI, machine learning, and digital twin technologies to predict drug candidate formulatability, assess biophysical properties, and select optimal lead formulations for clinical studies.
• Antibody and Antibody-Related Product Development Formulation development and analytical services for monoclonal antibodies, antibody-drug conjugates, and antibody-related therapeutics, addressing high-concentration formulation, viscosity, and stability challenges.
• Gene and Cell Therapy Development Formulation and analytical services for gene therapy and cell therapy products, including CAR-T cell starting material testing, viral vector characterization, AAV analysis, and lentiviral vector testing.
• Nucleic Acid Therapeutics Development Formulation and drug product development for nucleic acid therapeutics including mRNA, siRNA, antisense oligonucleotides, and LNP-based delivery systems.
• Viral Vector Characterization Services Specialized characterization and analytical services for viral vectors including AAV and lentiviral vectors used in gene therapy applications, featuring an optimized SV-AUC method for empty/full capsid differentiation.
• Vaccine Development Services Formulation development and characterization services for vaccine products including prophylactic and therapeutic vaccines, addressing antigen stability and shelf-life extension.
• Preclinical Drug Development Services Early-stage formulation and analytical services to establish solid formulation foundations and reduce risks before clinical entry for biologic drug candidates.
• Early-Phase Drug Development Services Drug development support with robust analytical methods as drug products advance toward clinical trials.
• Late-Phase and Commercialization Services Phase III and BLA filing support including formulation refinement and regulatory preparation for commercialization.
• Commercial Services Post-approval services including release and stability testing, manufacturing troubleshooting, and lifecycle management reformulation for commercialized biologics.

Quantifiable outcome

• 980 different biotherapeutics supported across various modalities
• +4 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Rentschler BiopharmacoreStrategic or Co-development Partner · 2 December 2025Rentschler Biopharma, a global contract development and manufacturing organization (CDMO), and Coriolis Pharma announced a strategic collaboration to offer integrated biopharmaceutical solutions. The partnership combines Rentschler Biopharma's bioprocess development and manufacturing expertise with Coriolis Pharma's formulation and analytical capabilities, providing clients a unified interface from early development through commercial manufacturing. The integrated service offering is available starting December 2025, with both organizations operating in Germany and the United States. The partnership aims to reduce tech transfer risks and accelerate product timelines.
• Frontier BiosolutionscoreStrategic or Co-development Partner · 16 October 2023Frontier Biosolutions is a specialized pharma services platform formed by KKR and Flerie to invest in companies specializing in advanced therapeutics. As the foundation of this platform, Frontier Biosolutions invested in Coriolis Pharma to expand its biologics and cell-gene therapy services. The partnership aims to leverage digital formulation approaches and AI technologies to enhance Coriolis's capabilities.
• INCOG BioPharma ServicesminorGTM or Marketing PartnerCoriolis Pharma co-hosts networking events with INCOG BioPharma Services during major industry conferences (TIDES, PEGS, ASGCT). The 'Science and Spirits – The Injectables Mixer' is an informal evening reception designed to foster new collaborations and strengthen professional relationships across the biologics and broader biopharma community.
• Stevanato GroupminorGTM or Marketing PartnerStevanato Group co-hosts networking events with Coriolis Pharma during major industry conferences (TIDES, PEGS, ASGCT). The collaboration at events like the 'Science and Spirits – The Injectables Mixer' brings together experts from biologics, gene and cell therapy, and the broader biopharma community.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Rentschler Biopharma: A German-headquartered CDMO specializing in biologics development and manufacturing. Directly comparable to Coriolis as both serve biopharma clients across biologics modalities, and the two companies have an active strategic collaboration announced in 2025.
• AGC Biologics: A global CDMO focused on biologics and advanced therapies including cell/gene therapy. Comparable to Coriolis as a similarly-sized specialized CDMO offering formulation development, analytical services, and GMP manufacturing for biologics.
• INCOG BioPharma Services: Specialized injectable drug product CDMO focused on biologics fill-finish and formulation. Directly comparable as a similarly-sized CDMO serving biologics developers, and an active marketing co-host of Coriolis's networking events.

Broad incumbents

• Lonza: One of the world's largest CDMOs with extensive biologics formulation, analytical, and manufacturing services. Comparable as a broad incumbent offering overlapping capabilities across the full biologics CMC spectrum that Coriolis addresses.
• Samsung Biologics: Large-scale global biologics CDMO providing process development, formulation, and GMP manufacturing. Comparable as a broad incumbent whose service portfolio overlaps materially with Coriolis's formulation and analytical offerings.
• Catalent: Major CDMO with biologics formulation, analytical, and drug product manufacturing capabilities across multiple modalities. Comparable to Coriolis as a broad incumbent serving biopharma with overlapping services.
• WuXi Biologics: One of the largest biologics CDMOs globally, offering end-to-end discovery, development, and manufacturing services. Comparable to Coriolis as a broad incumbent competing across the biologics formulation and analytical value chain.
• Eurofins Scientific: Global bioanalytical and contract laboratory services provider with extensive pharmaceutical testing offerings. Comparable to Coriolis in analytical, GMP release, and stability testing services supporting biopharma clients.
• Boehringer Ingelheim BioXcellence: Biopharmaceutical contract manufacturing arm of Boehringer Ingelheim, offering biologics process development, formulation, and commercial manufacturing. Comparable to Coriolis as a broad incumbent in biologics CMC services.

Emerging players

• Intertek Pharmaceutical Services: Provides analytical, formulation support, and GMP testing services to biopharma clients. Comparable to Coriolis as an analytical/formulation services provider, though with broader industry exposure beyond pure biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/coriolis-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coriolis Pharma